Abstract:Background The coinhibitory receptor Programmed Death-1 (PD-1) inhibits effector functions of activated T cells and prevents autoimmunity, however, cancer hijack this pathway to escape from immune attack. The costimulatory receptor glucocorticoid-induced TNFR related protein (GITR) is up-regulated on activated T cells and increases their proliferation, activation and cytokine production. We hypothesize that concomitant PD-1 blockade and GITR triggering would synergistically improve the effector functions of tumor-infiltrating T cells and increase the antitumor immunity. In present study, we evaluated the antitumor effects and mechanisms of combined PD-1 blockade and GITR triggering in a clinically highly relevant murine ID8 ovarian cancer model. Methods Mice with 7 days-established peritoneal ID8 ovarian cancer were treated intraperitoneally (i.p.) with either control, anti-PD-1, anti-GITR or anti-PD-1/GITR monoclonal antibody (mAb) and their survival was evaluated; the phenotype and function of tumor-associated immune cells in peritoneal cavity of treated mice was analyzed by flow cytometry, and systemic antigen-specific immune response was evaluated by ELISA and cytotoxicity assay. Results Combined anti-PD-1/GITR mAb treatment remarkably inhibited peritoneal ID8 tumor growth with 20% of mice tumor free 90 days after tumor challenge while treatment with either anti-PD-1 or anti-GITR mAb alone exhibited little antitumor effect. The durable antitumor effect was associated with a memory immune response and conferred by CD4 + cells and CD8 + T cells. The treatment of anti-PD-1/GITR mAb increased the frequencies of interferon-γ-producing effector T cells and decreased immunosuppressive regulatory T cells and myeloid-derived suppressor cells, shifting an immunosuppressive tumor milieu to an immunostimulatory state in peritoneal cavity. In addition, combined treatment of anti-PD-1/GITR mAb mounted an antigen-specific immune response as evidenced by antigen-specific IFN-γ production and cytolytic activity of spleen cells from treated mice. More importantly, combined treatment of anti-PD-1/GITR mAb and chemotherapeutic drugs (cisplatin or paclitaxel) further increased the antitumor efficacy with 80% of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast cancer models. Conclusions Combined anti-PD-1/GITR mAb treatment induces a potent antitumor immunity, which can be further promoted by chemotherapeutic drugs. A combined strategy of anti-PD-1/GITR mAb plus cisplatin or paclitaxel should be considered translation into clinic.

GITR Agonist Sensitizes MC38/OVA Tumor to CTLA4 Treatment by Attenuating Tregs in GITR HuGEMM

Optimal Target Saturation of Ligand-Blocking Anti-GITR Antibody IBI37G5 Dictates FcγR-Independent GITR Agonism and Antitumor Activity

Antitumor Activity of Expanded Human Tumor-Infiltrating Gammadelta T Lymphocytes.

GITR Costimulation Redirects Regulatory T Cells into Th9 Cells to Promote Antitumor Immunity (LYM8P.643)

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

Rational Design of Anti-Gitr-based Combination Immunotherapy

Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

Development of a Fully Human Anti‐gitr Antibody with Potent Antitumor Activity Using H2L2 Mice

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer

Combination with Toll-like Receptor 4 (TLR4) Agonist Reverses GITR Agonism Mediated M2 Polarization of Macrophage in Hepatocellular Carcinoma

Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types

GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy

RORt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells <i>via</i> TGF- signaling in cancer

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma

Intermittent MEK inhibition with GITR co-stimulation rescues T-cell function for increased efficacy with CTLA-4 blockade in solid tumor models

Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model

High-level of Intratumoral GITR+ CD4 T Cells Associate with Poor Prognosis in Gastric Cancer.

GITR Blockade Facilitates Treg Mediated Allograft Survival